Tempest Therapeutics, Inc. 8-K — AI Bull & Bear Analysis

The resignation of Stephen Brady, Michael Raab, and Christine Pellizzari marks a significant shift in the governance profile of Tempest Therapeutics. While the company maintains that the departures were not the result of operational disagreements, the simultaneous waiver of director fees creates a dichotomy for investors: it is either a prudent cash-preservation move to fund the pipeline or a desperate measure to extend a dwindling runway. The immediate impact is a leaner board, which could either accelerate decision-making or leave the company exposed to oversight gaps during a critical phase of its clinical development.